CoChat

Is schizophrenia a dopamine supersensitivity psychotic reaction?

Open access
Seeman, Mary V., Seeman, Philip · 2014 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
Cited by 81

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Adolf Meyer (1866-1950) did not see schizophrenia as a discrete disorder with a specific etiology but, rather, as a reaction to a wide variety of biopsychosocial factors. He may have been right. Today, we have evidence that gene mutations, brain injury, drug use (cocaine, amphetamine, marijuana, phencyclidine, and steroids), prenatal infection and malnutrition, social isolation and marginalization, can all result in the signs and symptoms of schizophrenia. This clinical picture is generally associated with supersensitivity to dopamine, and activates dopamine neurotransmission that is usually alleviated or blocked by drugs that block dopamine D2 receptors. While the dopamine neural pathway may be a final common route to many of the clinical symptoms, the components of this pathway, such as dopamine release and number of D2 receptors, are approximately normal in schizophrenia patients who are in remission. Postmortem findings, however, reveal more dimers of D1D2 and D2D2 receptors in both human schizophrenia brains and in animal models of schizophrenia. Another finding in animal models is an elevation of high-affinity state D2High receptors, but no radioactive ligand is yet available to selectively label D2High receptors in humans. It is suggested that synaptic dopamine supersensitivity in schizophrenia is an attempt at compensation for the original damage by heightening dopamine neurotransmission pathways (preparing the organism for fight or flight). The dopamine overactivity is experienced subjectively as overstimulation, which accounts for some of the clinical symptoms, with attempts at dampening down the stimulation leading to still other symptoms. Reaction and counter-reaction may explain the symptoms of schizophrenia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pnpbp.2013.10.003

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 50

  1. Brébion, 2009, Hallucinations and two types of free-recall intrusion in schizophrenia, Psychol Med, 39, 917, 10.1017/S0033291708004819 · DOI
  2. Buchsbaum, 2006, D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia, Schizophr Res, 85, 232, 10.1016/j.schres.2006.03.042 · DOI
  3. Byerly, 2005, Obsessive compulsive symptoms in schizophrenia: frequency and clinical features, Schizophr Res, 76, 309, 10.1016/j.schres.2005.02.004 · DOI
  4. Campos, 2010, Motor behavior abnormalities in drug naive patients with schizophrenia spectrum disorders, Mov Disord, 25, 1068, 10.1002/mds.23050 · DOI
  5. Charuchinda, 1987, Dopamine D2 receptors in the rat brain: autoradiographic visualization using a high-affinity selective agonist ligand, J Neurosci, 7, 1352, 10.1523/JNEUROSCI.07-05-01352.1987 · DOI · Paper page
  6. Chouinard, 1990, Severe cases of neuroleptic-induced supersensitivity psychosis: diagnostic criteria for the disorder and its treatment, Schizophr Res, 5, 21, 10.1016/0920-9964(91)90050-2 · DOI
  7. Chouvardas, 1996, The symbolic and literal in schizophrenic language, Perspect Psychiatr Care, 32, 20, 10.1111/j.1744-6163.1996.tb00502.x · doi:10.1111/j.1744-6163.1996.tb00502.x
  8. Corin, 1992, Positive withdrawal and the quest for meaning: the reconstruction of experience among schizophrenics, Psychiatry, 55, 266, 10.1080/00332747.1992.11024600 · DOI · Paper page
  9. Corripio, 2011, Density of striatal D2 receptors in untreated first-episode psychosis: an I(123)-IBZM SPECT study, Eur Neuropsychopharmacol, 21, 861, 10.1016/j.euroneuro.2011.03.004 · DOI
  10. Delay, 1952, Traitement des états d'excitation et d'agitation par une méthode médicamenteuse dérivée de l'hibernithérapie, Ann Med Psychol (Paris), 110, 267
  11. Double, 2007, Adolf Meyer's psychobiology and the challenge for biomedicine, Philos Psychiatr Psychol, 14, 331, 10.1353/ppp.0.0139 · doi:10.1353/ppp.0.0139
  12. Elvevåg, 2010, Conceptual combination and language in schizophrenia, Schizophr Res, 120, 238, 10.1016/j.schres.2010.04.006 · doi:10.1016/j.schres.2010.04.006
  13. Farde, 1990, D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride, Arch Gen Psychiatry, 47, 213, 10.1001/archpsyc.1990.01810150013003 · DOI · Paper page
  14. Garrett, 2003, Auditory hallucinations, source monitoring, and the belief that “voices” are real, Schizophr Bull, 29, 445, 10.1093/oxfordjournals.schbul.a007018 · DOI · Paper page
  15. Giannini, 1984, Comparison of chlorpromazine, haloperidol and pimozide in the treatment of phencyclidine psychosis: DA-2 receptor specificity, J Toxicol Clin Toxicol, 22, 573, 10.3109/15563658408992586 · DOI · Paper page
  16. Giannini, 2000, Acute ketamine intoxication treated by haloperidol: a preliminary study, Am J Ther, 7, 389, 10.1097/00045391-200007060-00008 · DOI
  17. Graff-Guerrero, 2009, The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study, Neuropsychopharmacology, 34, 1078, 10.1038/npp.2008.199 · DOI
  18. Hall, 1995, Effect of clozapine and risperidone on 5-HT2 and D2-dopamine receptor binding in the post-mortem human brain. An autoradiographic study, Eur Neuropsychopharmacol, 5, 19, 10.1016/0924-977X(94)00127-W · DOI
  19. Howes, 2012, The nature of dopamine dysfunction in schizophrenia and what this means for treatment, Arch Gen Psychiatry, 69, 776, 10.1001/archgenpsychiatry.2012.169 · DOI · Paper page
  20. Iyo, 2013, Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis, J Clin Psychopharmacol, 33, 398, 10.1097/JCP.0b013e31828ea95c · DOI · Paper page
  21. Kapur, 2005, Evidence for onset of antipsychotic effects within the first 24hours of treatment, Am J Psychiatry, 162, 939, 10.1176/appi.ajp.162.5.939 · DOI · Paper page
  22. Kegeles, 2010, Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography, Biol Psychiatry, 68, 634, 10.1016/j.biopsych.2010.05.027 · DOI
  23. Kimura, 2013, Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis, Schizophr Res, 145, 130, 10.1016/j.schres.2013.01.008 · DOI
  24. Laruelle, 1999, Increased dopamine transmission in schizophrenia: relationship to illness phases, Biol Psychiatry, 46, 56, 10.1016/S0006-3223(99)00067-0 · DOI · Paper page
  25. Lieberman, 1987, Provocative tests with psychostimulant drugs in schizophrenia, Psychopharmacology (Berl), 91, 415, 10.1007/BF00216006 · DOI · Paper page
  26. Madras, 2013, History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia, J Hist Neurosci, 22, 62, 10.1080/0964704X.2012.678199 · DOI
  27. Maor-Nof, 2013, Neurite pruning and neuronal cell death: spatial regulation of shared destruction programs, Curr Opin Neurobiol, 10.1016/j.conb.2013.06.007 · DOI
  28. Meyer, 1922, Constructive formulation of schizophrenia, Am J Psychiatry, 78, 355, 10.1176/ajp.78.3.355 · doi:10.1176/ajp.78.3.355
  29. Miller, 1993, Loss of striatal cholinergic neurons as a basis of tardive and l-dopa-induced dyskinesias, and neuroleptic-induced supersensitivity psychosis, Biol Psychiatry, 34, 713, 10.1016/0006-3223(93)90044-E · DOI
  30. Pappa, 2009, Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review, Psychol Med, 39, 1065, 10.1017/S0033291708004716 · DOI · Paper page
  31. Peluso, 2012, Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs, Br J Psychiatry, 200, 387, 10.1192/bjp.bp.111.101485 · DOI · Paper page
  32. Perreault, 2010, The dopamine D1–D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia, J Biol Chem, 285, 36625, 10.1074/jbc.M110.159954 · DOI · Paper page
  33. Samaha, 2013, Can antipsychotic treatment contribute to drug addiction in schizophrenia?, Prog Neuropsychopharmacol Biol Psychiatry
  34. Seeman, 2009, Schizophrenia model of elevated D2High receptors: haloperidol reverses the amphetamine-induced elevation in dopamine D2High, Schizophr Res, 109, 191, 10.1016/j.schres.2008.12.024 · DOI
  35. Seeman, 2012, Comment on “A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia” by Kinon, B.J. et al., J Clin Psychopharmacol, 32, 291, 10.1097/JCP.0b013e318248daaa · DOI
  36. Seeman, 2012, Dopamine agonist radioligand binds to both D2High and D2Low receptors, explaining why alterations in D2High are not detected in human brain scans, Synapse, 66, 88, 10.1002/syn.20987 · DOI
  37. Seeman, 2013, Schizophrenia and dopamine receptors, Eur Neuropsychopharmacol, 23, 999, 10.1016/j.euroneuro.2013.06.005 · DOI
  38. Seeman, 2013, Are dopamine D2 receptors out of control in psychosis?, Prog Neuropsychopharmacol Biol Psychiatry, 46, 146, 10.1016/j.pnpbp.2013.07.006 · DOI
  39. Seeman, 2013, Schizophrenia thalamus imaging: low benzamide binding to dopamine D2 receptors suggests fewer D2Short receptors and less presynaptic terminals, Psychiatry Res: Neuroimaging, 10.1016/j.pscychresns.2013.09.013 · DOI
  40. Seeman, 2013, Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia, Prog Neuropsychopharmacol Biol Psychiatry, 44, 178, 10.1016/j.pnpbp.2013.02.011 · DOI
  41. Seeman, 1975, Brain receptors for antipsychotic drugs and dopamine: direct binding assays, Proc Natl Acad Sci U S A, 72, 4376, 10.1073/pnas.72.11.4376 · DOI · Paper page
  42. Seeman, 1987, Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases, Neuropsychopharmacology, 1, 5, 10.1016/0893-133X(87)90004-2 · DOI · Paper page
  43. Seeman, 2009, Dopamine D2High receptors stimulated by phencyclidines, LSD, salvinorin A, and modafinil, Synapse, 63, 698, 10.1002/syn.20647 · DOI · Paper page
  44. Talvik, 2003, Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457, Int J Neuropsychopharmacol, 6, 361, 10.1017/S1461145703003699 · DOI · Paper page
  45. Talvik, 2006, Dopamine D2 receptor binding in drug-naïve patients with schizophrenia examined with raclopride-C11 and positron emission tomography, Psychiatry Res: Neuroimaging, 148, 165, 10.1016/j.pscychresns.2006.05.009 · DOI
  46. Tuppurainen, 2006, Midbrain dopamine D2/3 receptor binding in schizophrenia, Eur Arch Psychiatry Clin Neurosci, 256, 382, 10.1007/s00406-006-0649-3 · DOI
  47. Volkow, 2009, Substance use disorders in schizophrenia — clinical implications of comorbidity, Schizophr Bull, 35, 469, 10.1093/schbul/sbp016 · DOI · Paper page
  48. Wang, 2010, Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization, Mol Brain, 3, 25, 10.1186/1756-6606-3-25 · DOI · Paper page
  49. Yasuno, 2004, Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia, Am J Psychiatry, 161, 1016, 10.1176/appi.ajp.161.6.1016 · DOI · Paper page
  50. Yuhas, 2013, Throughout history, defining schizophrenia has remained a challenge (timeline), Sci Am Mind

Cited by

See all 81

Metadata

Authors
Seeman, M. V., & Seeman, P.
Venue
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Publisher
Elsevier BV
Published
2014-01
Volume
48
Pages
155-160
ISSN
0278-5846 (ISSN-L)
OpenAlex
W2048982528
Cited by
81
References
10
FWCI
5.10
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Is schizophrenia a dopamine supersensitivity psychotic reaction? https://app.cochat.ai/papers/10.1016/j.pnpbp.2013.10.003
The paper
Seeman, M. V., & Seeman, P. (2014). Is schizophrenia a dopamine supersensitivity psychotic reaction? Progress in Neuro-Psychopharmacology and Biological Psychiatry. https://doi.org/10.1016/j.pnpbp.2013.10.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.